Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former ATI exec Daphne Pai

Executive Summary

Ex-American Therapeutics, Inc. VP-regulatory affairs and quality control pleads guilty July 16 in Baltimore federal court to submitting false information to FDA in ANDA application for thiothixene 20 mg caps. ATI, which received sales of over $8 mil. for the antipsychotic, withdrew its thiothixene applications in January 1991 after an FDA inspection discovered fraudulent information in the ANDAs. According to a Justice Department release, Pai misrepresented the number of caps made and amount of ingredients used to produce an R&D lot of thiothixene. Pai faces a maximum of five year imprisonment and a $250,000 fine.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel